Oh but wait, sorry FY20 EBIT is depressed by one off impairment of a product, D&A is counted in Cost of sales. 56.2m of D&A attributed to CX140 product impairment. D&A was 284.4 in FY20 compared to 209.1m in FY19. In HY21 D&A is 103.7m so circa 200m annulalised like FY19.
Well, lets add back 80m odd to the FY20 'operational EBIT' because D&A is in cost of sales and was 'one off' inflated in FY20.
Capital Raising, page-14
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$294.73 |
Change
-0.270(0.09%) |
Mkt cap ! $142.6B | |||
| Open | High | Low | Value | Volume |
| $295.01 | $296.50 | $293.51 | $55.43M | 187.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 80 | $294.72 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $294.74 | 114 | 10 |
View Market Depth
| Last trade - 14.52pm 10/10/2024 (20 minute delay) ? |
| CSL (ASX) Chart |